ATE549031T1 - Impfstoffzusammensetzung zur prävention von cmv- infektionen - Google Patents

Impfstoffzusammensetzung zur prävention von cmv- infektionen

Info

Publication number
ATE549031T1
ATE549031T1 AT08804566T AT08804566T ATE549031T1 AT E549031 T1 ATE549031 T1 AT E549031T1 AT 08804566 T AT08804566 T AT 08804566T AT 08804566 T AT08804566 T AT 08804566T AT E549031 T1 ATE549031 T1 AT E549031T1
Authority
AT
Austria
Prior art keywords
vaccine composition
hcmv
preventing
cmv infections
preventing cmv
Prior art date
Application number
AT08804566T
Other languages
English (en)
Inventor
Robert F Pass
Gretchen Cloud
Original Assignee
Sanofi Pasteur
U A B Res Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40029466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE549031(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Pasteur, U A B Res Foundation filed Critical Sanofi Pasteur
Application granted granted Critical
Publication of ATE549031T1 publication Critical patent/ATE549031T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT08804566T 2007-09-21 2008-09-22 Impfstoffzusammensetzung zur prävention von cmv- infektionen ATE549031T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97423107P 2007-09-21 2007-09-21
PCT/EP2008/062640 WO2009037359A1 (en) 2007-09-21 2008-09-22 Vaccine composition for the prevention of cmv infections

Publications (1)

Publication Number Publication Date
ATE549031T1 true ATE549031T1 (de) 2012-03-15

Family

ID=40029466

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08804566T ATE549031T1 (de) 2007-09-21 2008-09-22 Impfstoffzusammensetzung zur prävention von cmv- infektionen

Country Status (5)

Country Link
US (1) US20090104227A1 (de)
EP (1) EP2203184B1 (de)
AT (1) ATE549031T1 (de)
CA (1) CA2699756A1 (de)
WO (1) WO2009037359A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2627352B1 (de) * 2010-10-15 2017-05-10 GlaxoSmithKline Biologicals S.A. Cytomegalovirus gb antigen
WO2013054199A2 (en) * 2011-10-12 2013-04-18 Novartis Ag Cmv antigens and uses thereof
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11524069B2 (en) 2017-09-13 2022-12-13 Sanofi Pasteur Human cytomegalovirus immunogenic composition
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
CA3199937A1 (en) 2020-10-28 2022-05-05 Sanofi Pasteur Liposomes containing tlr4 agonist, preparation and uses thereof
CN113842455B (zh) * 2021-08-27 2022-05-13 北京康乐卫士生物技术股份有限公司 一种新型冠状病毒疫苗的佐剂及其应用和新型冠状病毒二价重组疫苗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100064A (en) * 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
JP2009529576A (ja) * 2006-03-10 2009-08-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 持続感染または潜伏感染を引き起こすウイルスに対するワクチン

Also Published As

Publication number Publication date
US20090104227A1 (en) 2009-04-23
WO2009037359A1 (en) 2009-03-26
EP2203184A1 (de) 2010-07-07
CA2699756A1 (en) 2009-03-26
EP2203184B1 (de) 2012-03-14

Similar Documents

Publication Publication Date Title
ATE549031T1 (de) Impfstoffzusammensetzung zur prävention von cmv- infektionen
CY1117673T1 (el) Ανασυνδυασμενα αντιγονα rsv
MA33806B1 (fr) Inhibiteurs du virus de l'hepatite c
DE602007013618D1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
CL2013003360A1 (es) “compuestos derivados de 4-aril-n-[3-(sulfonimidoil)fenil]-1,3,5-triazin-2-amina sustituidos, inhibidores cdk; compuestos intermediarios, composición y combinación farmacéutica que los comprende; y su uso en el tratamiento de enfermedades hiperproliferativas, infecciosas inducidas por virus y/o cardiovasculares”. pct
EA201791675A1 (ru) Человеческие антитела к гликопротеину вируса эбола
CR20110091A (es) Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos
EA201600305A1 (ru) Вариант белка opc2 pcv2 и содержащие его вирусоподобные частицы
GEP20217260B (en) Antibody neutralizing human respiratory syncytial virus
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
EA201071087A1 (ru) Моноклональные антитела, способные взаимодействовать с множеством подтипов вируса гриппа а
UY34701A (es) Formas sólidas de un profármaco de nucleótidos de tiofosforamidato
EA201070794A1 (ru) Рекомбинантные антигены rsv
EA029939B8 (ru) Человеческие связывающие молекулы, обладающие способностью нейтрализовывать вирус гриппа h3n2, и их применение
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
BR112014004860A2 (pt) composições de anticorpo contra vírus da influenza
ME01140B (me) Virus goveđe virusne dijareje s modifikovanim erns proteinom
UA101814C2 (ru) Фактор, задействованный в латентной инфекции герпесвирусом, и его применение
WO2013106689A8 (en) Hcv ns3 protease inhibitors
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич
CL2009001195A1 (es) Adyuvante inmune que comprende un inhibidor de iap capaz de modular la actividad inmune; composicion farmaceutica y vacuna que lo comprenden; metodo para mejorar una respuesta inmune de un individuo; metodo para tratar un cancer en un individuo; metodo para tratar infeccion; metodo para tratar trastornos autoinmune.
MX2013004906A (es) Nuevos inhibidores especificos de la proteasa ns3 de hcv.
CL2011003002A1 (es) Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento.
BRPI0910884A2 (pt) composição imunogênica, método para tratar ou prevenir infecção ou doença estafilocócicas, e, uso de uma composição imunogênica.
EP2224943A4 (de) Verwendung eines humanen antikörpers zur neutralisierung von hepatitis-b-virus zur prävention oder behandlung von hepatitis-b-infektionen